Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intermittent vs Continuous Dabrafenib and Trametinib in BRAF-Mutant Melanoma
NCT02196181Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Sep 2014
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dabrafenib + trametinib, trametinib in melanoma, sponsored by National Cancer Institute. Started Sep 2014; status: active, not recruiting.
02
Drugs
dabrafenib + trametinibtrametinib
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02196181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02196181.